• PetMed Express posted a Q4 net loss of $4.1 million, or $0.19 per share, as net sales fell 15.6% to $42.8 million.
• Fiscal 2026 net loss widened to $57.3 million, or $2.74 per share, while net sales dropped 21.1% to $179 million.
• The full-year loss reflected a $26.7 million goodwill impairment charge, higher stock-based compensation, and $4.5 million of one-time whistleblower investigation costs.
• Management cited a modest sequential quarterly increase in Q4 net sales, pointing to cost reductions from strategic, operational, and technology initiatives.
• The board rejected two unsolicited cash buyout proposals received in December 2025 at $4 to $4.25 per share, while remaining open to future inbound interest.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PetMed Express Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606021605PRIMZONEFULLFEED9730663) on June 02, 2026, and is solely responsible for the information contained therein.